Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

Professor Sadleir says the product offers new hope

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
dhbuzz Member Profile
 
Followed By 8
Posts 1,776
Boards Moderated 0
Alias Born 03/01/19
160x600 placeholder
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol GlobeNewswire Inc. - 11/12/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/6/2019 8:17:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/6/2019 7:01:31 AM
Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights GlobeNewswire Inc. - 11/6/2019 6:45:00 AM
Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Zynerba Pharmace... PR Newswire (US) - 10/28/2019 10:42:00 AM
Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference GlobeNewswire Inc. - 10/25/2019 1:45:05 PM
Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Against Zynerba Pharmace... Business Wire - 10/25/2019 12:06:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:06:28 PM
Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 11:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/24/2019 7:05:14 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/18/2019 7:14:48 AM
Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental... GlobeNewswire Inc. - 9/18/2019 6:30:00 AM
New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Su... GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms... GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Zynerba Pharmaceuticals to Present at Two Upcoming Conferences GlobeNewswire Inc. - 9/3/2019 11:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/30/2019 4:27:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/30/2019 4:02:14 PM
Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Sym... GlobeNewswire Inc. - 8/29/2019 7:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 8/14/2019 6:00:55 AM
Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal ... GlobeNewswire Inc. - 8/7/2019 6:12:00 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/6/2019 8:14:23 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 7:05:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 7:01:50 AM
Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights GlobeNewswire Inc. - 8/6/2019 6:45:00 AM
Zynerba Pharmaceuticals to Present at Two Upcoming Conferences GlobeNewswire Inc. - 7/31/2019 8:00:00 AM
dhbuzz   Thursday, 10/03/19 02:00:58 PM
Re: dhbuzz post# 1976
Post # of 2106 
Professor Sadleir says the product offers new hope for children and adolescents experiencing severe epileptic seizures, who currently have few effective options for treatment.
The phase II clinical trial assessed the product's safety and efficacy in children and adolescents with Developmental and Epileptic Encephalopathies. These are the most difficult to treat epilepsies, and include the conditions Dravet Syndrome and Lennox-Gastaut syndrome. Patients with Developmental and Epileptic Encephalopathy have frequent severe seizures as well as severe cognitive and behavioral impairment.
Professor Sadleir says the gel not only reduced the number of epileptic seizures the children had, but also led to a reported improvement in behavioral and cognitive symptoms. It was also very well tolerated.
"These conditions are the most challenging and poorly controlled of all epilepsy disorders, and have a tremendous impact on the families involved.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist